ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,575.90
-1.39%
S&P ASX All Technology
2,970.40
-1.25%
Brent Oil
88.165
0.00%
US Dollar vs AUD
1.53139
0.00%
Bitcoin
63,861.02
0.71%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. INmune Bio Inc (INMB)

  7. INmune Bio Inc (INMB) News

INMB INmune Bio Inc

11.29
0.45 (4.15%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
INmune Bio Inc INMB NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.45 4.15% 11.29 10:00:00
Open Price Low Price High Price Close Price Previous Close
10.83 10.83 11.73 11.29 10.84
more quote information »

Recent News

Date Time Source Heading
25/4/202423:00GLOBEINmune Bio Inc. Announces $9.7 Million Registered Direct..
23/4/202422:00GLOBEINmune Bio Inc. Announces 24-Month Stability Validation of..
22/4/202422:00GLOBEINmune Bio Inc. Raises Approximately $4.8 Million in Gross..
08/4/202422:00GLOBEINmune Bio Inc. Presents Data on INB03’s Role as an Immune..
29/3/202407:01GLOBEINmune Bio Inc. Announces Year End 2023 Results and Provides..
27/3/202407:01GLOBEINmune Bio Inc. to Report Fourth Quarter 2023 Financial..
13/3/202423:00GLOBEINmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives..
06/3/202400:00GLOBEINmune Bio Reports Significant EEG Improvement in..
13/2/202401:00GLOBEINmune Bio to Participate in the Oppenheimer 34th Annual..
07/2/202401:00GLOBEINmune Bio to Participate in Baird’s Biotech Discovery..
31/1/202400:02EDGAR2Form 8-K - Current report
31/1/202400:00GLOBEINmune Bio Announces FDA Removal of Clinical Hold for..
17/1/202400:30GLOBEELEVAI Labs, Inc. Acquires Worldwide License Agreement for..
03/1/202408:00EDGAR2Form 8-K - Current report
03/1/202400:00GLOBEINmune Bio Announces First Patient Dosed in a Phase 1/2..
19/12/202308:15EDGAR2Form 8-K - Current report
19/12/202308:05EDGAR2Form 8-A12B/A - Registration of securities [Section 12(b)]:..
19/12/202308:01EDGAR2Form 8-K - Current report
19/12/202308:01GLOBEINmune Bio Provides Update Regarding Global Alzheimer’s..
30/11/202308:00EDGAR2Form 8-K - Current report
30/11/202300:00GLOBEINmune Bio Inc. Demonstrates that INB03 Enhances the Uptake..
28/11/202308:00EDGAR2Form 8-K - Current report
28/11/202300:00GLOBEINmune Bio Receives EMA’s Authorization in France and Spain..
16/11/202308:13EDGAR2Form 8-K - Current report
16/11/202301:00GLOBEINmune Bio Inc. Announces Expansion of Phase II Clinical..
14/11/202303:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202307:13EDGAR2Form 8-K - Current report
02/11/202307:10GLOBEINmune Bio Inc. Announces Third Quarter 2023 Results and..
02/11/202307:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202307:25EDGAR2Form 8-K - Current report
31/10/202323:00GLOBEINmune Bio Inc. Patent Claims Covering INB16 Cell Line and..
31/10/202300:07GLOBEINmune Bio Inc. Presents Preclinical Data at SITC 2023..
17/10/202323:00GLOBEINmune Bio Inc. Presents New Biomarker and Feasibility Data..
17/10/202300:00GLOBEINmune Bio Inc. to Report Third Quarter 2023 Financial..
07/9/202323:10EDGAR2Form 8-K - Current report
07/9/202323:00GLOBEINmune Bio Inc. to Present at Baird Global Healthcare..
06/9/202306:00EDGAR2Form 8-K - Current report
05/9/202322:00GLOBEINmune Bio Inc. Announces Approval of Clinical Trial..
17/8/202306:41EDGAR2Form 8-K - Current report
17/8/202306:39EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/8/202306:01EDGAR2Form 8-K - Current report
08/8/202306:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202306:00GLOBEINmune Bio Inc. Announces Second Quarter 2023 Results and..
02/8/202320:02EDGAR2Form 8-K - Current report
01/8/202322:00GLOBEINmune Bio Inc. to Present at the BTIG Virtual ..
31/7/202322:00GLOBEINmune Bio, Inc. to Report Second Quarter 2023 Financial..
28/7/202306:43EDGAR2Form 8-K - Current report
15/7/202306:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/7/202306:00EDGAR2Form 8-K - Current report
13/7/202303:23EDGAR2Form 144 - Report of proposed sale of securities

Your Recent History

NASDAQ
INMB
INmune Bio
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved